News
XNCR
12.36
-1.24%
-0.16
Top Xencor Executive Quietly Cashes Out a Chunk of Company Stock
TipRanks · 1d ago
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
TipRanks · 1d ago
Weekly Report: what happened at XNCR last week (0406-0410)?
Weekly Report · 2d ago
Weekly Report: what happened at XNCR last week (0330-0403)?
Weekly Report · 04/06 09:05
Weekly Report: what happened at XNCR last week (0323-0327)?
Weekly Report · 03/30 09:05
This SAP Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Benzinga · 03/24 16:02
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
TipRanks · 03/24 16:01
Stocks Settle Lower as Iran War Boosts Crude Oil and Bond Yields
Barchart · 03/24 15:43
Microsoft reinstated, Ralph Lauren upgraded: Wall Street’s top analyst calls
TipRanks · 03/24 13:42
Xencor Price Target Cut to $13.00/Share From $18.00 by JP Morgan
Dow Jones · 03/24 12:17
Xencor Cut to Neutral From Overweight by JP Morgan
Dow Jones · 03/24 12:17
JP Morgan Downgrades Xencor to Neutral, Lowers Price Target to $13
Benzinga · 03/24 12:08
JPMorgan downgrades Xencor on lack of ‘needle-moving’ catalysts
TipRanks · 03/24 10:20
Stocks Fall as Iran War Drags On
Barchart · 03/24 10:19
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Xencor (XNCR)
TipRanks · 03/24 10:10
Xencor downgraded to Neutral from Overweight at JPMorgan
TipRanks · 03/24 09:25
XENCOR INC <XNCR.O>: JP MORGAN CUTS TO NEUTRAL FROM OVERWEIGHT; CUTS TARGET PRICE TO $13 FROM $18
Reuters · 03/24 09:08
Stocks Pressured as Crude Oil Prices and Bond Yields Climb
Barchart · 03/24 09:07
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco
Reuters · 03/24 07:39
Weekly Report: what happened at XNCR last week (0316-0320)?
Weekly Report · 03/23 09:05
More
Webull provides a variety of real-time XNCR stock news. You can receive the latest news about Xencor through multiple platforms. This information may help you make smarter investment decisions.
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.